ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

13 May 2025 08:00:00 By Nasdaq GlobeNewswire

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

09 May 2025 13:05:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

27 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

06 Dec 2024 14:30:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

07 Nov 2024 13:05:02 By Nasdaq GlobeNewswire

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

22 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

17 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

03 Sep 2024 13:01:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

01 Aug 2024 13:05:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

31 Jul 2024 05:05:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

09 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

12 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

11 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming June Conferences

29 May 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

17 May 2024 14:00:00 By Nasdaq GlobeNewswire

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

15 May 2024 13:05:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming May Conferences

02 May 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

15 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

11 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

03 Apr 2024 04:00:00 By Nasdaq GlobeNewswire